GH Research (NASDAQ:GHRS) Price Target Raised to $46.00

GH Research logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Guggenheim raised its GH Research price target to $46 from $40 and maintained a Buy rating, implying 151.78% upside from the stock’s current price.
  • Analysts overall have a Moderate Buy consensus and an average price target of $44; 10 analysts rate the stock Buy, one Hold, and one Sell.
  • GH Research shares fell 2.6% and opened at $18.27. The company reported a quarterly loss of $0.18 per share, narrower than analysts’ $0.31 loss estimate.
  • Five stocks to consider instead of GH Research.

GH Research (NASDAQ:GHRS - Get Free Report) had its target price hoisted by Guggenheim from $40.00 to $46.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price target suggests a potential upside of 151.78% from the stock's current price.

A number of other research firms also recently weighed in on GHRS. Cantor Fitzgerald raised their price target on shares of GH Research from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Wells Fargo & Company initiated coverage on shares of GH Research in a report on Monday, July 27th. They set an "overweight" rating and a $44.00 price target on the stock. Wall Street Zen upgraded shares of GH Research from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright dropped their price objective on shares of GH Research from $65.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, New Street Research set a $65.00 target price on shares of GH Research in a research report on Monday, August 10th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.00.

View Our Latest Research Report on GH Research

GH Research Stock Down 2.6%

Shares of GHRS stock opened at $18.27 on Wednesday. The business has a fifty day simple moving average of $21.92 and a 200 day simple moving average of $21.66. The company has a market cap of $1.25 billion, a P/E ratio of -19.23 and a beta of 1.31. GH Research has a twelve month low of $12.04 and a twelve month high of $31.44.

GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.13. As a group, equities research analysts anticipate that GH Research will post -1.20 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

Large investors have recently bought and sold shares of the company. Troluce Capital Advisors LLC increased its stake in shares of GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company's stock valued at $13,926,000 after buying an additional 617,260 shares during the period. Braidwell LP bought a new position in GH Research in the 2nd quarter valued at approximately $5,571,000. Marshall Wace LLP boosted its position in GH Research by 46.3% during the 3rd quarter. Marshall Wace LLP now owns 68,298 shares of the company's stock worth $1,604,000 after buying an additional 21,601 shares during the period. Renaissance Technologies LLC acquired a new stake in GH Research during the 1st quarter worth approximately $290,000. Finally, Squarepoint Ops LLC acquired a new stake in GH Research during the 2nd quarter worth approximately $495,000. 56.90% of the stock is currently owned by institutional investors.

About GH Research

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Further Reading

Analyst Recommendations for GH Research (NASDAQ:GHRS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GH Research Right Now?

Before you consider GH Research, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.

While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines